Calcific aortic valve disease: A consensus summary from the alliance of investigators on calcific aortic valve disease

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 34, Issue 11, 2014, Pages 2387-2393

  Yutzey, Katherine E ^a   Demer, Linda L ^b   Body, Simon C ^c   Huggins, Gordon S ^d   Towler, Dwight A ^e   Giachelli, Cecilia M ^f   Hofmann Bowman, Marion A ^g   Mortlock, Douglas P ^h   Rogers, Melissa B ⁱ   Sadeghi, Mehran M ^j,k   Aikawa, Elena ^c  

^a CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e BURNHAM INSTITUTE   (United States)

^f UNIVERSITY OF WASHINGTON   (United States)

^g UNIVERSITY OF CHICAGO   (United States)

^h VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

ⁱ RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

^j YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^k VA CONNECTICUT HEALTHCARE SYSTEM   (United States)

more..

Author keywords

Aortic valve stenosis; Calcification; Inflammation

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; ANTIBIOTIC AGENT; ANTIINFLAMMATORY AGENT; APOLIPOPROTEIN A; BIOLOGICAL MARKER; FLUORODEOXYGLUCOSE F 18; METHOTREXATE; MICRORNA; OXIDIZED LOW DENSITY LIPOPROTEIN; VASODILATOR AGENT;

AORTA VALVE DISEASE; BICUSPID AORTIC VALVE; BLOOD VESSEL CALCIFICATION; BONE DEVELOPMENT; CALCIFIC AORTIC VALVE DISEASE; CARDIAC PATIENT; CONSENSUS DEVELOPMENT; DISEASE COURSE; ENDOCRINE FUNCTION; GENE CONTROL; GENETIC PREDISPOSITION; HEMODYNAMICS; HUMAN; MECHANICAL STRESS; MEDICAL RESEARCH; METABOLIC REGULATION; METABOLIC SYNDROME X; MINERAL METABOLISM; MOLECULAR IMAGING; NATIONAL HEALTH ORGANIZATION; OSTEOCLAST; PATHOGENESIS; PATHOPHYSIOLOGY; POPULATION RESEARCH; REVIEW; RISK ASSESSMENT; SIGNAL TRANSDUCTION; AORTA VALVE; AORTIC VALVE STENOSIS; CALCINOSIS; HEART DEFECTS, CONGENITAL; HEART SURGERY; HEART VALVE DISEASES; HEART VALVE REPLACEMENT; PATHOLOGY; PHYSIOLOGY; TRENDS;

AORTIC VALVE; AORTIC VALVE STENOSIS; BIOMEDICAL RESEARCH; CALCINOSIS; CARDIAC SURGICAL PROCEDURES; HEART DEFECTS, CONGENITAL; HEART VALVE DISEASES; HEART VALVE PROSTHESIS IMPLANTATION; HEMODYNAMICS; HUMANS; SIGNAL TRANSDUCTION;

EID: 84911913843     PISSN: 10795642     EISSN: 15244636     Source Type: Journal    
DOI: 10.1161/ATVBAHA.114.302523     Document Type: Review

References (70)

1. Aikawa E, Schoen FJ. Calcific and degenerative heart valve disease. In: Stone J, Homeister JM, Willis MS, eds. Cellular and Molecular Pathobiology of Cardiovascular Disease. Elsevier: London, UK; 2014:161-181.
2. Nishimura RA, Otto CM, Bonow RO, Carabello BA, Erwin JP 3rd, Guyton RA, O'Gara PT, Ruiz CE, Skubas NJ, Sorajja P, Sundt TM 3rd, Thomas JD; ACC/AHA Task Force Members. 2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: executive summary: a repo rt of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;129:2440-2492.
3. Lindman BR, Bonow RO, Otto CM. Current management of calcific aortic stenosis. Circ Res. 2013;113:223-237.
4. Rajamannan NM, Evans FJ, Aikawa E, Grande-Allen KJ, Demer LL, Heistad DD, Simmons CA, Masters KS, Mathieu P, O'Brien KD, Schoe n FJ, Towler DA, Yoganathan AP, Otto CM. Calcific aortic valve disease: not simply a degenerative process: A review and agenda for research from the National Heart and Lung and Blood Institute Aortic Stenosis Working Group. Executive summ ary: Calcific aortic valve disease-2011 update. Circulation. 2011;124:1783-1791.
5. Desai CS, Roselli EE, Svensson LG, Bonow RO. Transcatheter aortic valve replacement: current status and future directions. Semin Thorac Cardiovasc Surg. 2013;25:193-196.
6. Rementer CW, Wu M, Buranaphatthana W, Yang HY, Scatena M, Giachelli CM. An inducible, ligand-independent receptor activator of NF -?B gene to control osteoclast differentiation from monocytic precursors. PLoS One. 2013;8:e84465.
7. Rossebø AB, Pedersen TR, Boman K, et al; SEAS Investigators. Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. N Engl J Med. 2008;359:1343-1356.
8. Chan KL,Teo K,Dumesnil JG,Ni A,Tam J; ASTRONOMER Investigators. Effect of Lipid lowering with rosuvastati n on progression of aortic stenosis: results of the aortic stenosis progression observation: measuring effects of rosuvastatin (ASTRONOMER) trial. Circulation. 2010;121:306-314.
9. Everett BM, Pradhan AD, Solomon DH, Paynter N, Macfadyen J, Zaharris E, Gupta M, Clearfield M, Libby P, Hasan AA, Glynn RJ, Ridker PM. Rationale and design of the Cardiovascular Inflammation Reduction Trial: a test of the inflammatory h ypothesis of atherothrombosis. Am Heart J. 2013;166:199-207.e15.
10. Stewart BF, Siscovick D, Lind BK, Gardin JM, Gottdiener JS, Smith VE, Kitzman DW, Otto CM. Clinical factors associa ted with calcific aortic valve disease. Cardiovascular Health Study. J Am Coll Cardiol. 1997;29:630-634.
11. Arsenault BJ, Boekholdt SM, Dubé MP, Rhéaume E, Wareham NJ, Khaw KT, Sandhu MS, Tardif JC. Lipoprotein(a) levels, genotype, and incident aortic valve stenosis: a prospective mendelian randomization study and replication in a case-control cohort. Circ Cardiovasc Genet. 2014;7:304-310.
12. Nasir K, Katz R, Takasu J, Shavelle DM, Detrano R, Lima JA, Blumenthal RS, O'Brien K, Budoff MJ. Ethnic differences between extra-coronary measures on cardiac computed tomography: multi-ethnic study of atherosc lerosis (MESA). Atherosclerosis. 2008;198:104-114.
13. Owens DS, Katz R, Takasu J, Kronmal R, Budoff MJ, O'Brien KD. Incidence and progression of aortic valve calcium in the Multi-ethnic S tudy of Atherosclerosis (MESA). Am J Cardiol. 2010;105:701-708.
14. Ix JH, Shlipak MG, Katz R, Budoff MJ, Shavelle DM, Probstfield JL, Takasu J, Detrano R, O'Brien KD. Kidney function and aortic valve and mitral annular calcification in the Multi-Ethnic Study of Atherosclerosis (MESA). Am J Kidney Dis. 2007;50:412-420.
15. Katz R, Budoff MJ, Takasu J, Shavelle DM, Bertoni A, Blumenthal RS, Ouyang P, Wong ND, O'Brien KD. Relationship of metabolic syndrome with incident aortic valve calcium and aortic valve calcium progression: the Multi-Ethnic Study of Atherosclerosis (MESA ). Diabetes. 2009;58:813-819.
16. Briand M, Lemieux I, Dumesnil JG, Mathieu P, Cartier A, Després JP, Arsenault M, Couet J, Pibarot P. Metabolic syndrome negatively influences disease progression and prognosis in aortic stenosis. J Am Coll Cardiol. 2006;47:2229-2236.
17. Thanassoulis G, Campbell CY, Owens DS, et al; CHARGE Extracoronary Calcium Working Group. Genetic assoc iations with valvular calcification and aortic stenosis. N Engl J Med. 2013;368:503-512.
18. Kamstrup PR, Tybjæ rg-Hansen A, Nordestgaard BG. Elevated lipoprotein(a) and risk of aortic valve stenosis in the general population. J Am Coll Cardiol. 2014;63:470-477.
19. Mahmut A, Boulanger MC, El Husseini D, Fournier D, Bouchareb R, Després JP, Pibarot P, Bossé Y, Mathieu P. Elevated expression of lipoprotein-associated phospholipase A2 in calcific aortic valve disease: implications for valve mineralization. J Am Coll Cardiol. 2014;63:460-469.
20. Lemaire SA, McDonald ML, G uo DC, et al. Genome-wide association study identifies a susceptibility locus for thoracic aortic aneurysms and aortic dissections spanning FBN1 at 15q21.1. Nat Genet. 2011;43:996-1000.
21. Leone O, Biagini E, Pacini D, Zagnoni S, Ferlito M, Graziosi M, Di Bartolomeo R, Rapezzi C. The elusive link between aortic wall histology and echocardiographic anatomy in bicuspid aortic valve: implications for prophylactic surgery. Eur J Cardiothorac Surg. 2012;41:322-327.
22. Conti CA, Della Corte A, Votta E, Del Viscovo L, Bancone C, De Santo LS, Redaelli A. Biomechanical implications of the congenital bicuspi d aortic valve: a finite element study of aortic root function from in vivo data. J Thorac Cardiovasc Surg. 2010;140:890- 896, 896.e1.
23. Dyer LA, Kirby ML. The role of secondary heart field in cardiac development. Dev Biol. 2009;336:137-144.
24. Kirby ML, Waldo KL. Role of neural crest in congenital heart disease. Circulation. 1990;82:332-340.
25. Side r KL, Blaser MC, Simmons CA. Animal models of calcific aortic valve disease. Int J Inflam. 2011;2011:364310.
26. Gould ST, Srigunapalan S, Simmons CA, Anseth KS. Hemodynamic and cellular response feedback in calcific aortic valve disease. Circ Res. 2013;113:186-197.
27. Rabkin E, Aikawa M, Stone JR, Fukumoto Y, Libby P, Schoen FJ. Activated interstitial myofibrobla sts express catabolic enzymes and mediate matrix remodeling in myxomatous heart valves. Circulation. 2001;104:2525-2532.
28. Latif N, Sarathchandra P, Chester A, Yacoub M. Expression of smooth muscle cell markers and co-activators in calcified aortic valves. Eur Heart J. In press.
29. Poggianti E,Venneri L,Chubuchny V,Jambrik Z,Baroncini L.A.,Picano E. Aortic valve sclerosis is associated with systemic endothelial dysfunction. J Am Coll Cardiol. 2003;41:136-141.
30. Boströ m KI, Rajamannan NM, Towler DA. The regulation of valvular and vascular sclerosis by osteogenic morphogens. Circ Res. 2011;109:564-577.
31. Galeone A, Paparella D, Colucci S, Grano M, Brunetti G. The role of TNF-?and TNF superfamily members in the pathogenesis of calcific aortic valvular disease. ScientificWorldJournal. 2013;2013:875363.
32. Byon CH, Javed A, Dai Q, Kappes JC, Clemens TL, Darley-Usmar VM, McDonald JM, Chen Y. Oxidative stress induces vascular calcification through modulation of the osteogenic transcription factor Runx2 by AKT signaling. J Biol Chem. 2008;283:15319- 15327.
33. New SE, Goettsch C, Aikawa M, Marchini JF, Shibasaki M, Yabusaki K, Libby P, Shanahan CM, Croce K, Aikawa E. Macrophage-derived matrix vesicles: an alternative novel mechanism for mi crocalcification in atherosclerotic plaques. Circ Res. 2013;113:72-77.
34. Cheng SL, Shao JS, Halstead LR, Distelhorst K, Sierra O, Towler DA. Activation of vascular smooth muscle parath yroid hormone receptor inhibits Wnt/beta-catenin signaling and aortic fibrosis in diabetic arteriosclerosis. Circ Res. 2010;107:271-282.
35. Iwata S, Walker MD, Di Tullio MR, Hyodo E, Jin Z, Liu R, Sacco RL, Homma S, Silverberg SJ. Aortic valve calcification in mild primary hyperparathyroidism. J Clin Endocrinol Metab. 2012;97:132-137.
36. Brown JM, Vaidya A. Interactions b etween adrenal-regulatory and calcium-regulatory hormones in human health. Curr Opin Endocrinol Diabetes Obes. 2014;21:193-201.
37. O'Brien KD, Shavelle DM, Caulfield MT, McDonald TO, Olin-Lewis K, Otto CM, Probstfield JL. Association of angiotensin-converting enzyme with low-density lipoprotein in aortic valvular lesions and in human plasma. Circulation. 2002;106:2224-2230.
38. Arishiro K, Hoshiga M, Negoro N, Jin D, Takai S, Miyazaki M, Ishihara T, Hanafusa T. Angiotensin receptor-1 blocker inhibits atherosclerotic changes and endothelial disruption of the aortic valve in hypercholesterolemic rabbits. J Am Coll Cardiol. 2007;49:1482-1489.
39. Rattazzi M, Bertacco E, Del Vecchio A, Puato M, Faggin E, Pauletto P. Aortic valve calcification in chronic kidney disease. Nephrol Dial Transplan t. 2013;28:2968-2976.
40. Shanahan CM, Crouthamel MH, Kapustin A, Giachelli CM. Arterial calcification in chronic kidney disease: key roles for calcium and phosphate. Circ Res. 2011;109:697-711.
41. Wu M, Rementer C, Giachelli CM. Vascular calcification: an update on mechanisms and challenges in treatment. Calcif Tissue Int. 2013;93:365-373.
42. Cher tow GM, Burke SK, Raggi P; Treat to Goal Working Group. Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int. 2002;62:245-252.
43. Raggi P, Bommer J, Chertow GM. Valvular calcification in hemodialysis patients randomized to calcium-based phosphorus binders or sevelamer. J Heart Valve Dis. 2004;13:134-141.
44. Salaü n C, Leroy C, Rousseau A, Boitez V, Beck L, Friedlander G. Identification of a novel transport-independent function of PiT1/SLC20A1 in the regulation of TNF-induced apoptosis. J Biol Chem. 2010;285:3440 8-34418.
45. El Husseini D, Boulanger MC, Fournier D, Mahmut A, Bossé Y, Pibarot P, Mathieu P. High expression of the Pi-transporter SLC20A1/Pit1 in calcific aortic valve disease promotes mineralization th rough regulation of Akt-1. PLoS One. 2013;8:e53393.
46. Otto CM, Kuusisto J, Reichenbach DD, Gown AM, O'Brien KD. Characterization of the early lesion of ?degenerative' valvular aortic steno sis. Histological and immunohistochemical studies. Circulation. 1994;90:844-853.
47. Ueland T, Aukrust P, Dahl CP, Husebye T, Solberg OG, Tønnessen T, Aakhus S, Gullestad L. Osteoprote gerin levels predict mortality in patients with symptomatic aortic stenosis. J Intern Med. 2011;270:452-460.
48. Sigrist MK, Levin A, Er L, McIntyre CW. Elevated osteoprotegerin is associated wi th all-cause mortality in CKD stage 4 and 5 patients in addition to vascular calcification. Nephrol Dial Transplant. 2009;24:3157-3162.
49. Simpson CL, Lindley S, Eisenberg C, Basalyga DM, Starche r BC, Simionescu DT, Vyavahare NR. Toward cell therapy for vascular calcification: osteoclast-mediated demineralization of calcified elastin. Cardiovasc Pathol. 2007;16:29-37.
50. Wirrig EE,Yutzey KE. Developmental pathways in CAVD. In: Aikawa E, ed. Calcific Aortic Valve Disease. Croatia: InTech, 2013, 59-104.
51. Wirrig EE, Yutzey KE. Conserved transcriptional regulatory mechanisms in aortic valve development and disease. Arterioscler Thromb Vasc Biol. 2014;34:737-741.
52. Garg V, Muth AN, Ransom JF, Schluterman MK, Barnes R, King IN, Grossfeld PD, Srivastava D. Muta tions in NOTCH1 cause aortic valve disease. Nature. 2005;437:270-274.
53. Nigam V, Srivastava D. Notch1 represses osteogenic pathways in aortic valve cells. J Mol Cell Cardiol. 2009;47:828-834.
54. Nus M, MacGrogan D, Mart ínez-Poveda B, Benito Y, Casanova JC, Fernández-Avilés F, Bermejo J, de la Pompa JL. Diet-induced aortic valve disease in mice haploinsufficient for the Notch p athway effector RBPJK/CSL. Arterioscler Thromb Vasc Biol. 2011;31:1580-1588.
55. Caira FC, Stock SR, Gleason TG, McGee EC, Huang J, Bonow RO, Spelsberg TC, McCarthy PM, Rahimtoola SH, Rajamannan NM. Human degenerative valve disease is associated with up-regulation of low-density lipoprotein receptor-related protein 5 receptor-mediated bone formation. J Am Coll Cardiol. 2006;47:1707-1712.
56. Rajamannan NM, Subramaniam M, Caira F, Stock SR, Spelsberg TC. Atorvastatin inhibits hypercholesterolemia-induced calcification in the aortic valves via the Lrp5 receptor pathway. Circulation. 2005;112(9 supp l):I229-I234.
57. Ankeny RF, Thourani VH, Weiss D, Vega JD, Taylor WR, Nerem RM, Jo H. Preferential activation of SMAD1/5/8 on the fibrosa endothelium in calcified human aortic valves-association with low BMP antagonists and SMAD6. PLoS One. 2011;6:e20969.
58. Luna-Zurita L, Prados B, Grego-Bessa J, Luxán G, del Monte G, Benguría A, Adams RH, Pérez-Pomares JM, de la Pompa JL. Integration of a Not ch-dependent mesenchymal gene program and Bmp2-driven cell invasiveness regulates murine cardiac valve formation. J Clin Invest. 2010;120:3493-3507.
59. Miller JD, Weiss RM, Heistad DD. Calcific aortic valve stenosis: methods, models, and mechanisms. Circ Res. 2011;108:1392-1412.
60. Cheek JD, Wirrig EE, Alfieri CM, James JF, Yutzey KE. Differential activation of valvulogenic, chondrog enic, and osteogenic pathways in mouse models of myxomatous and calcific aortic valve disease. J Mol Cell Cardiol. 2012;52:689-700.
61. Goettsch C, Hutcheson JD, Aikawa E. MicroRNA in cardiovascular calcification: focus on targets and extracellular vesicle delivery mechanisms. Circ Res. 2013;112:1073-1084.
62. Nigam V, Sievers HH, Jensen BC, Sier HA, Simpson PC, Srivastava D, Mohame d SA. Altered microRNAs in bicuspid aortic valve: a comparison between stenotic and insufficient valves. J Heart Valve Dis. 2010;19:459-465.
63. Yanagawa B, Lovren F, Pan Y, Garg V, Quan A, Tang G, Singh KK, Shukla PC, Kalra NP, Peterson MD, Verma S. miRNA-141 is a novel regulator of BMP-2-mediated calcification in aortic stenosis. J Thorac Cardiovasc Surg. 2012;144:256-262.
64. . Ikonomidis JS, Ivey CR, Wheeler JB, Akerman AW, Rice A, Patel RK, Stroud RE, Shah AA, Hughes CG, Ferrari G, Mukherjee R, Jones JA. Plasma biomarkers for distinguishing etiologic subtypes of thoracic a ortic aneurysm disease. J Thorac Cardiovasc Surg. 2013;145:1326-1333.
65. Holliday CJ, Ankeny RF, Jo H, Nerem RM. Discovery of shear-and sidespecific mRNAs and miRNAs in human aortic valvular end othelial cells. Am J Physiol Heart Circ Physiol. 2011;301:H856-H867.
66. Fotinos A, Nagarajan N, Martins AS, Fritz DT, Garsetti D, Lee AT, Hong CC, Rogers MB. Bone morphogenetic protein-focused strategies to induce cytotoxicity in lung cancer cells. Anticancer Res. 2014;34:2095-2104.
67. Marincheva-Savcheva G, Subramanian S, Qadir S, Figueroa A, Truong Q, Vijayakumar J, Brady TJ, Hoffmann U, Tawakol A. Imaging of the aortic valve using fluorodeoxyglucose positron emission tomography increased valvular fluorodeoxyglucose uptake in aortic stenosis. J Am Coll Cardiol. 2011;57:2507- 2515.
68. Dweck MR, Jone C, Joshi NV, et al. Assessment of valvular calcification and inflammation by positron emission tomography in patients with aortic stenosis. Circulation 2012;125:76-86.
69. Aikawa E, Nahrendorf M, Sosnovik D, Lok VM, Jaffer FA, Aikawa M, Weissleder R. Multimodality molecular imaging identifies proteolytic and osteogenic activities in early aortic valve disease. Circul ation. 2007;115:377-386.
70. Aikawa E, Otto CM. Look more closely at the valve: imaging calcific aortic valve disease. Circulation. 2012;125:9-11.